Company intelligence / Profile preview

AFMB

Heidelberg, Baden-Württemberg, Germanyafmb.bike ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Affimed has demonstrated proof-of-concept for its ICE® molecules in early clinical studies, showing activation of innate immunity against tumors. Their lead candidates are advancing through various stages of clinical development targeting relapsed/refractory blood cancers and solid tumors. Recent updates indicate ongoing trials but also financial challenges leading to potential delisting from Nasdaq.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibody fragment
Industry: Biotech

Partnerships

Select partnerships with major pharmaceutical companies—specific partners not listed publicly as of latest available data.

Beyond the preview

Go deeper on AFMB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFMB.

Explore the full profile